Friday, 16 October 2026European Markets

SIF HOLDING Stock Is 12% Up At Session Start Today

Loading stream...

(VIANEWS) - Shares of SIF HOLDING (AEX-Index: SIFG.AS) rose by a staggering 12.64% to €12.30 at 10:09 EST on Tuesday, following the last session's downward trend. AEX-Index is jumping 0.21% to €764.27, following the last session's upward trend. This seems, so far, a somewhat up trend exchanging session today.

About SIF HOLDING

Sif Holding N.V. manufactures and sells tubular steel foundations for offshore wind farms and metal structures, for the offshore industry in the Netherlands and internationally. The company operates through three segments: Wind, Marshalling, and Other. It engages in the production and delivery of monopiles, parts of metal structures, pipes, pipe structures, and components, as well as cans and cones, transition pieces, pin piles, jacket legs, and pile sleeves. The company rents logistical area and facilities; and delivers logistical services to the offshore wind industry. It serves energy companies, developers, and fabricators, as well as engineering, procurement, construction, and installation contractors. Sif Holding N.V. was founded in 1948 and is headquartered in Roermond, the Netherlands.

Earnings Per Share

As for profitability, SIF HOLDING has a trailing twelve months EPS of €0.28.

PE Ratio

SIF HOLDING has a trailing twelve months price to earnings ratio of 43.16. Meaning, the purchaser of the share is investing €43.16 for every euro of annual earnings.

Volume

Today's last reported volume for SIF HOLDING is 70947 which is 909.63% above its average volume of 7027.

More news about SIF HOLDING (SIFG.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com